Russell Investments Group Ltd. Sells 34,989 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Russell Investments Group Ltd. lowered its position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 60.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,316 shares of the company's stock after selling 34,989 shares during the quarter. Russell Investments Group Ltd. owned 0.06% of SI-BONE worth $327,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. American Century Companies Inc. grew its position in shares of SI-BONE by 11.0% during the 4th quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after acquiring an additional 236,167 shares during the period. Harbor Capital Advisors Inc. increased its position in SI-BONE by 35.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company's stock worth $11,791,000 after buying an additional 220,555 shares during the last quarter. First Eagle Investment Management LLC bought a new stake in shares of SI-BONE in the fourth quarter valued at $2,600,000. Tocqueville Asset Management L.P. purchased a new stake in SI-BONE in the 4th quarter worth about $2,383,000. Finally, JPMorgan Chase & Co. lifted its holdings in SI-BONE by 57.7% during the fourth quarter. JPMorgan Chase & Co. now owns 280,453 shares of the company's stock valued at $3,932,000 after purchasing an additional 102,660 shares during the last quarter. 98.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SIBN has been the topic of several research reports. Needham & Company LLC boosted their price target on shares of SI-BONE from $20.00 to $24.00 and gave the company a "buy" rating in a research report on Tuesday, February 25th. Truist Financial reiterated a "buy" rating and set a $22.00 price target (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of SI-BONE in a report on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $24.40.

SI-BONE Price Performance

SI-BONE stock traded down $0.63 during mid-day trading on Wednesday, hitting $13.65. 246,215 shares of the company traded hands, compared to its average volume of 359,291. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $19.16. The stock has a market cap of $579.48 million, a price-to-earnings ratio of -14.84 and a beta of 1.02. The stock has a fifty day moving average price of $14.77 and a 200-day moving average price of $14.65.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. On average, equities analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Insider Buying and Selling at SI-BONE

In other SI-BONE news, SVP Michael A. Pisetsky sold 3,128 shares of SI-BONE stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the transaction, the senior vice president now directly owns 244,878 shares of the company's stock, valued at $3,462,574.92. The trade was a 1.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anthony J. Recupero sold 3,311 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total transaction of $46,850.65. Following the sale, the insider now directly owns 284,555 shares of the company's stock, valued at $4,026,453.25. The trade was a 1.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,776 shares of company stock worth $96,644 over the last ninety days. Insiders own 3.90% of the company's stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.